Biopharma bites: Job cuts at Novartis, fresh funding for MeiraGTx and Fore, plus Boehringer's latest deal

Novartis is cutting hundreds of jobs globally in 2026 as part of a multi‑year restructuring to save about $1 billion, with up to 8,000 positions at risk—roughly 7% of its global workforce—slated for elimination over the next few years. In the U.S., additional layoffs at its East Hanover, N.J. headquarters push total job reductions there to about 250 in 2026, while the company is also closing its Wehr, Germany manufacturing site and cutting around 220 jobs there by 2028.

Novartis expects net global workforce reduction of only 1–2% over the next two to three years, given that it will also add new roles, particularly in areas linked to rare‑disease medicines and growth assets.

Separate reports indicate that MeiraGTx Holdings (MGTX) has seen fresh investor interest in 2026, with stock sentiment buoyed by ongoing clinical programs in gene therapy, though there is no single, widely publicized new funding round clearly identified in top search results; rather, recent coverage emphasizes share‑price performance and pipeline updates rather than a discrete capital raise.

There is no prominent, clearly documented new funding round in 2026 for a company named “Fore” in the biopharma space; the snippets returned do not contain a matching recent financing event for such a firm, so any mention of “Fore” in the headline may either refer to a lesser‑known private company or a typographical/branding error.

The latest deal news relevant to Boehringer is not explicitly surfaced in the retrieved results; however, absent a specific headline in these snippets, the most recent major Boehringer deal in late 2025–2026 widely reported was its acquisition of Anthos Therapeutics and expansion of its cardiovascular portfolio, but newer 2026 transactions would require more targeted data than this search provides.